– Reuters
Home Newsfeeds U.S. Fda Announces Evusheld Is Not Currently Authorized For Emergency Use In U.S.; FDA Data Shows Evusheld Is Unlikely To Be Active Against Certain Sars-Cov-2 Variants
U.S. Fda Announces Evusheld Is Not Currently Authorized For Emergency Use In U.S.; FDA Data Shows Evusheld Is Unlikely To Be Active Against Certain Sars-Cov-2 Variants
– Reuters
Related Posts
BWS Financial Maintains Buy on Garrett Motion, Maintains $15 Price Target
February 15, 10:34 AM
BWS Financial analyst Hamed Khorsand maintains Garrett Motion (NASDAQ:GTX) with a Buy and maintains $15 price target.
Visa And PayPal Got CNBC Fast Money Call Of The Day With Investors Choosing These Final Trades
September 21, 1:31 PM
CNBC’s "Fast Money: Halftime Report" delivers market-moving news to investors.
The commentary delivered by hosts of the show often moves the stocks mentioned. The information is collected and refined using Benzinga Pro’s News Tool. Benzinga Pro users can access this information by using the News tool on any workstation.
Top 5 Consumer Stocks That May Explode This Quarter
July 24, 7:49 AM
The most oversold stocks in the consumer discretionary sector presents an opportunity to buy into undervalued companies.